Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Neven

Showing results (91-100 of 140) with videos related to

Pageof 14
Sort By:
Breast Cancer Research and Treatment|May 17, 2018
Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancerG Hoste, K Punie, H Wildiers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2013
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementH A Azim, S Michiels, F Zagouri, et al.
ESMO Open|March 19, 2025
Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trialN Harbeck, V Dieras, K A Gelmon, et al.
Cancer Research|June 11, 1998
Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogenP Dal Cin, D Timmerman, I Van den Berghe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2013
Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancersO Brouckaert, A Schoneveld, C Truyers, et al.
Gynecologic Oncology|January 26, 2020
Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-DS Timmerman, A S Van Rompuy, T Van Gorp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2009
Activity of fulvestrant in HER2-overexpressing advanced breast cancerJ F R Robertson, G G Steger, P Neven, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 17, 2010
Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancerH Wildiers, P Neven, M R Christiaens, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|September 30, 2010
Effect of cancer prevalence on the use of risk-assessment cut-off levels and the performance of mathematical models to distinguish malignant from benign adnexal massesA Daemen, D Jurkovic, C Van Holsbeke, et al.
Breast Cancer Research and Treatment|May 13, 2014
A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMIA Lintermans, K Van Asten, H Wildiers, et al.
Pageof 14

Showing results (91-100 of 140) with videos related to

Sort By:
Pageof 14
Breast Cancer Research and Treatment|May 17, 2018
Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancerG Hoste, K Punie, H Wildiers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2013
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementH A Azim, S Michiels, F Zagouri, et al.
ESMO Open|March 19, 2025
Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trialN Harbeck, V Dieras, K A Gelmon, et al.
Cancer Research|June 11, 1998
Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogenP Dal Cin, D Timmerman, I Van den Berghe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2013
Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancersO Brouckaert, A Schoneveld, C Truyers, et al.
Gynecologic Oncology|January 26, 2020
Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-DS Timmerman, A S Van Rompuy, T Van Gorp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2009
Activity of fulvestrant in HER2-overexpressing advanced breast cancerJ F R Robertson, G G Steger, P Neven, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 17, 2010
Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancerH Wildiers, P Neven, M R Christiaens, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|September 30, 2010
Effect of cancer prevalence on the use of risk-assessment cut-off levels and the performance of mathematical models to distinguish malignant from benign adnexal massesA Daemen, D Jurkovic, C Van Holsbeke, et al.
Breast Cancer Research and Treatment|May 13, 2014
A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMIA Lintermans, K Van Asten, H Wildiers, et al.
Pageof 14